Real‐world weight‐loss effectiveness of glucagon‐like peptide‐1 agonists among patients with type 2 diabetes: A retrospective cohort study
Obesity2023Vol. 31(2), pp. 537–544
Citations Over TimeTop 10% of 2023 papers
Abstract
In this real-world study of more than 2400 patients with overweight or obesity and type 2 diabetes, starting a GLP-1 agonist at standard glycemic control doses was associated with modest weight loss through 72 weeks.
Related Papers
- → A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation(2014)23 cited
- → Endogenous glucagon‐like peptide (GLP)‐1 as alternative for GLP‐1 receptor agonists: Could this work and how?(2023)17 cited
- → Dual Receptor Agonist for Type 2 Diabetes(2018)1 cited
- → Glucagon-like peptide-1 (GCG; GLP-1); GLP-1 receptor (GLP1R; GLP-1R)(2009)1 cited
- → The role of glucagon like peptide - 1 (GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus(2019)